Today: 23 January 2026
Subscribe
Browse Category

NYSE:AMP News 17 January 2026 - 18 January 2026

American Express stock rebounds before the long weekend as Trump’s rate-cap plan stays in play

American Express stock rebounds before the long weekend as Trump’s rate-cap plan stays in play

New York, Jan 18, 2026, 15:39 EST — Market closed Shares of American Express Company rose 2.08% on Friday to $364.79, beating a modestly softer Wall Street ahead of the long weekend. Trading volume topped recent averages, though the stock still sits roughly 6% below its Dec. 12 peak. (MarketWatch) The bounce comes with a policy overhang still hanging over…
18 January 2026
·······
Palantir stock slides into MLK break — what to watch before PLTR earnings

Palantir stock slides into MLK break — what to watch before PLTR earnings

New York, Jan 18, 2026, 06:13 EST — Market closed Palantir Technologies Inc (PLTR) shares closed down 3.4% on Friday at $170.96, after swinging between $170.03 and $182.12, with about 59.5 million shares traded. The drop came as U.S. stocks ended little changed in a choppy session and logged modest weekly losses, with Treasury yields rising after fresh uncertainty around…
18 January 2026
······
Super Micro Computer (SMCI) stock price jumps 11% after-hours — chip rally and options expiry set up next week

Super Micro Computer (SMCI) stock price jumps 11% after-hours — chip rally and options expiry set up next week

New York, Jan 16, 2026, 18:17 (EST) — After-hours Super Micro Computer shares jumped roughly 11% to $32.64 in after-hours trading on Friday, after fluctuating between $29.62 and $32.97 during the session. Around 78.8 million shares traded hands. Chip stocks rallied into the close, pushing an index of semiconductors up 1.2% as U.S. markets edged higher ahead of the long…
17 January 2026
········

Stock Market Today

  • AngioDynamics (ANGO) Stock Shows 81.88% Upside Despite Profitability Challenges
    January 23, 2026, 8:39 AM EST. AngioDynamics, Inc. (NASDAQ: ANGO) offers an 81.88% potential upside with an average analyst target price of $19.33, driven by three buy ratings and zero sell or hold recommendations. The New York-based medical device firm specializes in treating peripheral vascular disease and oncology, with a current market cap of $438.14 million and stock price at $10.63. However, the company faces profitability hurdles, reflected in a negative forward P/E of -96.64, a -0.67 EPS, and a -15.26% return on equity. Revenue grew 9%, and free cash flow remains positive at $300,625, signaling operational strength. Technical signals are mixed: oversold RSI at 17.38 hints at rebound potential, while negative MACD suggests short-term weakness. Investors should balance the growth promise of products like Auryon and AlphaVac against financial and market risks.
Go toTop